Citation

McCoyd M. Neurol. Clin. 2013; 31(3): 827-845.

Copyright

(Copyright © 2013, Elsevier Publishing)

DOI

10.1016/j.ncl.2013.03.010

PMID

unavailable

Abstract

Multiple sclerosis (MS) is one of the most common neurologic disorders that affects young people. The disorder has long been associated with clinical relapses and a disabling course. However, there has been a rapid expansion in the available treatment options for MS, and new insights into existing therapies, as decades of research has begun to produce tangible treatment results leading to newly approved an emerging therapies. © 2013 Elsevier Inc.

Language: en

Keywords

human; suicide; pathogenesis; review; clinical feature; priority journal; physical examination; disease course; practice guideline; nuclear magnetic resonance imaging; alternative medicine; drug safety; food and drug administration; drug fatality; drug efficacy; diarrhea; drug tolerability; nausea; erythema; lymphocytopenia; proteinuria; relapse; recurrence risk; side effect; pruritus; tablet; leukocyte count; aspiration pneumonia; drug approval; corticotropin; nausea and vomiting; clinical decision making; azathioprine; methylprednisolone; multiple sclerosis; flushing; hair loss; mycophenolic acid 2 morpholinoethyl ester; nuclear magnetic resonance; methotrexate; systolic blood pressure; beta1a interferon; glatiramer; molecular mimicry; cyclophosphamide; treatment duration; upper respiratory tract infection; lymphocyte count; blood brain barrier; prednisone; mitoxantrone; natalizumab; herpes zoster; randomized controlled trial (topic); alemtuzumab; fingolimod; vitamin supplementation; retina macula edema; upper abdominal pain; vitamin D; fumaric acid dimethyl ester; teriflunomide; phase 3 clinical trial (topic); Alemtuzumab (Lemtrada); BG-12 (Tecfidera); Fingolimod (Gilenya); herpes simplex encephalitis; McDonald criteria; Natalizumab (Tysabri); sphingosine 1 phosphate receptor; Teriflunomide (Aubagio); Vitamin D